CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
Placebos +2 moredrug
Likely dose
Ketamine 0.5 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03102736
NCT03102736Phase 2Completed

Pharmacologic Attenuation of Ketamine Using Nitroprusside

Icahn School of Medicine at Mount Sinai·interventional·Posted Apr 6, 2017·Updated Jul 2, 2020

In Brief

A Phase 2 clinical trial evaluating Placebos, Ketamine, and 1 other intervention for Depression. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The purpose of this study is to test the effects of the medication ketamine and the medication called nitroprusside in patients with major depression. Ketamine has both good and bad effects. Some studies have shown that ketamine improves depression. However, studies have also shown that it causes strange and sometimes unpleasant sensations referred to "psychotic" or "dissociative" symptoms. An example of a psychotic symptom would be hearing or seeing something that in reality is not there. The study team would like to see if nitroprusside can prevent the reported bad effects of ketamine without blocking the reported good effects. This might make ketamine a better treatment for depression.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedApr 6, 2017
Enrollment StartFeb 14, 2017
Primary CompletionJun 12, 2019
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 9.2 years ago

Interventions

Placebosdrug

Placebo saline

Ketaminedrug

0.5 mg/kg ketamine

Nitroprussidedrug

0.5 mcg/kg nitroprusside